Target- |
MechanismImmunomodulators |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date10 May 2022 |
单臂、开放性、多中心临床试验评价人凝血酶原复合物治疗乙型血友病的有效性和安全性
[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of human prothrombin complex therapy in the treatment of hemophilia B
评价华兰生物工程重庆有限公司人凝血酶原复合物治疗乙型血友病的有效性和安全性。
[Translation] To evaluate the efficacy and safety of human prothrombin complex produced by Chongqing Hualan Biotechnology Co., Ltd. in the treatment of hemophilia B.
单臂、开放性、多中心临床试验评价人凝血因子Ⅷ治疗甲型血友病的有效性和安全性
[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of human coagulation factor VIII in the treatment of hemophilia A
评价华兰生物工程重庆有限公司生产的人凝血因子Ⅷ制剂治疗甲型血友病患者的安全性和有效性。
[Translation] To evaluate the safety and efficacy of human coagulation factor VIII preparation produced by Chongqing Hualan Bioengineering Co., Ltd. in the treatment of patients with hemophilia A.
100 Clinical Results associated with Hualan Biological Engineering Chongqing Co., Ltd.
0 Patents (Medical) associated with Hualan Biological Engineering Chongqing Co., Ltd.
100 Deals associated with Hualan Biological Engineering Chongqing Co., Ltd.
100 Translational Medicine associated with Hualan Biological Engineering Chongqing Co., Ltd.